These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9021918)

  • 1. IgM-mediated opsonization and cytotoxicity in the shark.
    McKinney EC; Flajnik MF
    J Leukoc Biol; 1997 Feb; 61(2):141-6. PubMed ID: 9021918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of cell-mediated cytotoxicity by shark 19S IgM.
    Pettey CL; McKinney EC
    Cell Immunol; 1988 Jan; 111(1):28-38. PubMed ID: 3338093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc receptor for shark IgM.
    Haynes L; Fuller L; McKinney EC
    Dev Comp Immunol; 1988; 12(3):561-71. PubMed ID: 3169353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shark spontaneous cytotoxicity: characterization of the regulatory cell.
    Haynes L; McKinney EC
    Dev Comp Immunol; 1991; 15(3):123-34. PubMed ID: 2060682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of 19S IgM antibodies with restricted heterogeneity from sharks.
    Clem LW; Leslie GA
    Proc Natl Acad Sci U S A; 1971 Jan; 68(1):139-41. PubMed ID: 5276285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phylogeny of immunoglobulin structure and function. I. Immunoglobulins of the lemon shark.
    Clem LW; Small PA
    J Exp Med; 1967 May; 125(5):893-920. PubMed ID: 4164694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.
    Leidi M; Gotti E; Bologna L; Miranda E; Rimoldi M; Sica A; Roncalli M; Palumbo GA; Introna M; Golay J
    J Immunol; 2009 Apr; 182(7):4415-22. PubMed ID: 19299742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversity and repertoire of IgW and IgM VH families in the newborn nurse shark.
    Rumfelt LL; Lohr RL; Dooley H; Flajnik MF
    BMC Immunol; 2004 May; 5():8. PubMed ID: 15132758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noncoordinate expression of J-chain and Blimp-1 define nurse shark plasma cell populations during ontogeny.
    Castro CD; Ohta Y; Dooley H; Flajnik MF
    Eur J Immunol; 2013 Nov; 43(11):3061-75. PubMed ID: 23897025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opsonic, cytotoxic, precipitating, blocking of bacterial adherence, and other activities of monoclonal IgE antibody compared with IgA and IgM.
    Tlaskalová-Hogenová H; Simecková J; Vĕtvicka V; Fornůsek L; TalaFantová M; Mancal P
    Immunology; 1984 Nov; 53(3):427-33. PubMed ID: 6436172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage-like effector of spontaneous cytotoxicity from the shark.
    McKinney EC; Haynes L; Droese AL
    Dev Comp Immunol; 1986; 10(4):497-508. PubMed ID: 3817246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of 19S and 7S IgM antibodies during the immune response in the nurse shark.
    Voss EW; Sigel MM
    J Immunol; 1971 May; 106(5):1323-9. PubMed ID: 5574406
    [No Abstract]   [Full Text] [Related]  

  • 16. CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity.
    Jodo S; Hohlbaum AM; Xiao S; Chan D; Strehlow D; Sherr DH; Marshak-Rothstein A; Ju ST
    J Immunol; 2000 Nov; 165(10):5487-94. PubMed ID: 11067901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies.
    Macarrón Palacios A; Grzeschik J; Deweid L; Krah S; Zielonka S; Rösner T; Peipp M; Valerius T; Kolmar H
    Front Immunol; 2020; 11():560244. PubMed ID: 33324393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of human B cells and inhibition of their terminal differentiation by monoclonal anti-mu antibodies.
    Maruyama S; Kubagawa H; Cooper MD
    J Immunol; 1985 Jul; 135(1):192-9. PubMed ID: 3923101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
    Lefebvre ML; Krause SW; Salcedo M; Nardin A
    J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies against leucoagglutinin-reactive human T lymphocyte surface components. Two antibodies which inhibit cell-mediated cytotoxicity at a post-binding stage.
    Vargas-Cortes M; Hammarström ML; Hammarström S; Hellström U; Perlmann P
    Eur J Immunol; 1986 Jul; 16(7):795-801. PubMed ID: 3522246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.